PMID- 32067834 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210514 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 307 DP - 2020 May 15 TI - Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis. PG - 75-81 LID - S0167-5273(19)34945-9 [pii] LID - 10.1016/j.ijcard.2020.02.025 [doi] AB - AIMS: Primary prevention implantable cardioverter defibrillator (ICD) is not generally recommended in New York Heart Association (NYHA) I class patients with dilated cardiomyopathy (DCM). This study sought to assess the competing risk of sudden cardiac death (SCD) in DCM patients with left ventricular ejection fraction (EF) /=3 months of guideline-directed medical therapy were included. The risk of SCD and SCD/malignant ventricular arrhythmias (MVA) was assessed in NYHA I vs. NYHA II and NYHA III groups by competing risk analysis. RESULTS: NYHA I patients were younger, had higher EF and smaller left atrium, were less likely receiving mineral corticoid receptor antagonists. The cumulative incidence of SCD (p = 0.92) and SCD/MVA (p = 0.42) did not differ between NYHA I vs NYHA II-III classes. NYHA class did not influence the association between ICD and SCD risk (p for interaction = 0.125). CONCLUSIONS: In this cohort of DCMs, patients with EF